CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: BYR-181019 | Healthcare
Historical data: 2018 - 2023
Forecast period: 2024 - 2031
Quantitative units: Revenue in USD million and CAGR from 2024 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Chronic Obstructive Pulmonary Disorder Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET
7.1 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE (2018-2031) (USD MILLION)
8.1 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
8.2 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
9.1 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
9.2 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
10.1 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)
10.2 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)
11.1 NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
11.2 NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
11.3 NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
11.4 NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
11.5 NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
11.6 NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
12.1 EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
12.2 EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
12.3 EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
12.4 EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
12.5 EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
12.6 EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
13.1 ASIA PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
13.2 ASIA PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
13.3 ASIA PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
13.4 ASIA PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
13.5 ASIA PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
13.6 ASIA PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
14.1 LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>
14.2 LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
14.3 LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
14.4 LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
14.5 LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
14.6 LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>
16.1 AstraZeneca
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Boehringer Ingelheim
16.3 GSK
16.4 Novartis
16.5 Teva Pharmaceuticals
16.6 Ache Laboratorios Farmaceuticos
16.7 Almirall
16.8 Aquinox Pharmaceuticals
16.9 Ario Pharma
16.10 Asmacure
16.11 Astellas Pharma
16.12 BioMarck Pharmaceuticals
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
Market By Type- Short-Acting Bronchodilators
- Corticosteroids
- Methylxanthines
- Long-Acting Bronchodilators
- Phosphodiesterase-4 Inhibitors
Based on the end-use, the global Chronic Obstructive Pulmonary Disorder market classified into
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Companies
AstraZeneca
Boehringer Ingelheim
GSK
Novartis
Teva Pharmaceuticals
Ache Laboratorios Farmaceuticos
Almirall
Aquinox Pharmaceuticals
Ario Pharma
Asmacure
Astellas Pharma
BioMarck Pharmaceuticals
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.